Wadler v. Bio-Rad Laboratories, Inc.

141 F. Supp. 3d 1005, 2015 U.S. Dist. LEXIS 144468, 2015 WL 6438670
CourtDistrict Court, N.D. California
DecidedOctober 23, 2015
DocketCase No. 15-cv-02356-JCS
StatusPublished
Cited by3 cases

This text of 141 F. Supp. 3d 1005 (Wadler v. Bio-Rad Laboratories, Inc.) is published on Counsel Stack Legal Research, covering District Court, N.D. California primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Wadler v. Bio-Rad Laboratories, Inc., 141 F. Supp. 3d 1005, 2015 U.S. Dist. LEXIS 144468, 2015 WL 6438670 (N.D. Cal. 2015).

Opinion

ORDER GRANTING IN PART AND DENYING IN PART DEFENDANTS’ MOTION TO DISMISS

JOSEPH C. SPERO, Chief Magistrate Judge

I. INTRODUCTION

Plaintiff Sanford Wadler brings a whis-tleblower action against Defendants Bio-Rad Laboratories, Inc. (“Bio-Rad”) and the individual members of Bio-Rad’s Board of Directors, contending he was wrongfully terminated in retaliation for investigating and reporting to Bio-Rad’s upper-level management possible violations of the Foreign Corrupt Practices Act (“FCPA”) in China. Wadler asserts claims under the Sarbanes-Oxley Act, the Dodd-Frank Act, [1008]*1008and California state law. Presently before the Court is Defendants’ Motion to Dismiss the Complaint (“Motion”), which came on for hearing on September 4, 2015 at 9:30 a.m. The parties submitted supplemental briefs on September 25, 2015. For the reasons stated below, the Motion is GRANTED in part and DENIED in part.1

II. BACKGROUND

A. The Complaint

In the Complaint, Wadler alleges that he became Bio-Rad’s general counsel in 1989 and served in that position for nearly 25 years. Compl. ¶ 2. According to Plaintiff, Bio-Rad is a Fortune 1000 company that manufactures and sells products and equipment around the world. Id. ¶ 6. Because Bio-Rad sells many of its products to hospitals, universities, and similar public entities and officials, it must abide by the terms of the FCPA, which “forbids the company or its agents from engaging in bribery and kickback schemes involving public officials and requires that companies maintain accurate accounting records and put in place adequate internal controls or face significant fines and possible criminal punishment.” Id. ¶¶ 4, 6; Opposition at 2 (citing 15 U.S.C, §§ 78dd-2, 78ff).

■ Wadler alleges that “[i]n 2009, Bio-Rad’s corporate officers became aware that certain of its employees and agents in Vietnam, Thailand, and Russia may have violated provisions of the FCPA.” Id. ¶ 14. Bio-Rad “recently admitted the existence of such violations in a, consent decree and agreed to pay $55.1 million in fines for this conduct as it related to Bio-Rad’s operations in Thailand, Vietnam, and Russia.” Id. ¶¶ 14-15. After discovering the illegal activities in Thailand, Vietnam and Russia, Bio-Rad hired the law firm Steptoe and Johnson LLP to investigate whether Bio-Rad employees were engaging in bribery in China — -“a country where Bio-Rad had significantly greater amounts of sales than Thailand, Vietnam, or Russia and where corruption is notoriously widespread.” Id. ¶¶ 16-17. According to Wadler, Steptoe & Johnson concluded that “there was no evidence of improper payments.” Id. ¶ 17.

Wadler alleges that in 201T, he discovered that although Bio-Rad’s sales in China were “in the hundreds of millions of dollars over a number of years,” there was virtually no documentation supporting Bio-Rad’s China-related sales. Id. ¶¶- 20-21. Wadler was concerned that the lack of documentation-was a violation of the FCPA’s record-keeping requirements and that it “suggested efforts to conceal violations of the FCPA’s anti-bribery provisions.” Id. ¶ 22. Wadler “repeatedly tried to obtain documents from Bio-Rad’s CEO, CFO, and other key executives, but despite, indicating that they would assist in tracking down such documents, these executives repeatedly failed to do so.” Id ¶ 21. According to Wadler, in 2012, he was “finally able to uncover a few documents” and they provided “unambiguous evidence of potential bribery” by Bio-Rad in China. Id. ¶ 24. He also learned in early 2013 that “certain standard language concerning the need for FCPA" compliance had been removed (without his knowledge or approval) from documents translated into Chinese and used for Bio-Rad’s operations in China. Id. ¶ 27.

Wadler alleges that the CEO, CFO and other members' of management repeatedly “stonewall[edj” him, leading him to “become suspicious that corruption issues in China were known to senior management, and that management was intentionally blocking his efforts to uncover evidence of bribery and related misconduct.” Id. ¶ 28. [1009]*1009Wadler alleges that he then took his concerns to the Audit Committee of the Board of Directors, which reengaged Steptoe and Johnson to investigate these violations. Id. ¶¶ 29-30. Wadler objected to the appointment of Steptoe and' Johnson on the basis that it “had a clear conflict of interest,” having failed to uncover in 2011 any FCPA violations in China; according to Wadler, “any finding in 2013 would have demonstrated Steptoe’s prior malpractice.” Id. ¶ 30.

Wadler alleges that Steptoe and Johnson again concluded that there was no evidence of improper payments in connection with Bio-Rad’s China sales and reported its finding at a meeting in March 2013 between Bio-Rad, Steptoe and Johnson and its outside auditor, Ernst & Young. Id. ¶ 32. According to Wadler, he challenged this conclusion at the meéting and' stated that “thirty percent of the documents concerning Bio-Rad’s China operations that he had reviewed contained discrepancies related to the shipment volume.” Id In response, the Steptoe and Johnson partner who had conducted the investigations in both -2011 and 2013 stated that he had “simply not addressed those issues.” Id. Wadler alleges that he “was effectively shut out of the investigation over his repeated objections that he should be included.” Id. ¶ 33.

Soon after the March 2013 meeting, ■ on June 7, 2013, Bio-Rad terminated Wadler. Id. ¶ 35. The termination was “effectuated by the CEO” but the decision to terminate Wadler “was made by a vote of the entire Board.” Id. In particular, Wadler alleges that Board members Louis Drapeau, Alice N. Schwartz, Albert J. Hillman and Deborah Neff made the decision to terminate Wadler and “were aware that Wádler had reported bribery, books-and-records violations, and related misconduct to persons with supervisory authority over him and to other persons at Bio-Rad 'who had the authority to investigate, discover, or terminate‘such misconduct.” Id. ¶ 38. Wadler further alleges that he was terminated because he was investigating potential FCPA violations and because he reported his concerns “up the ladder” ■ “when it became clear that-the company was not taking reasonable steps to investigate and remedy FCPA violations.” Id. ¶ 39:

Wadler alleges that throughout his employment he had always reported to the CEO, first David Schwartz and then Norman Schwartz, and that he had never been told that his work was deficient; in December 2012, -Norman Schwartz gave Wadler a positive performance review,- promoted him to Executive Vice President and gáve him a raise. Id. ¶ 37.-According to Wadler, at the time of his termination, Bio-Rad had been scheduled to -give a report to the Securities and • Exchange Commission (“SEC”) and the Department of Justice (“DOJ”) just a few weeks later “regarding the status of Bio-Rad’s internal FCPA investigations.” Id. ¶ 41. Bio-Rad’s outside counsel, Davis Polk, gave the presentation at that meeting. Id. ¶ 42.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
141 F. Supp. 3d 1005, 2015 U.S. Dist. LEXIS 144468, 2015 WL 6438670, Counsel Stack Legal Research, https://law.counselstack.com/opinion/wadler-v-bio-rad-laboratories-inc-cand-2015.